Allogenetics

Executive Summary

Allogenetics is a German biotech founded in 2021, developing a novel approach to prevent organ rejection by making donor organs immunologically invisible, thereby eliminating the need for lifelong immunosuppression. This shifts the paradigm from suppressing the recipient's immune system to modifying the graft to evade immune detection. The company aims to improve graft survival, recipient quality of life, and expand the pool of available organs. Currently at Phase 1 stage, Allogenetics is advancing its proprietary platform through preclinical studies, targeting first-in-human trials. Despite early-stage risk, the innovative strategy addresses a critical unmet need in transplantation, with potential to transform standard of care.

Upcoming Catalysts (preview)

• Q3 2026Completion of GLP Toxicology Studies70% success
• Q1 2027IND/CTA Filing for First-in-Human Trial60% success
• Q4 2027Initial Phase 1 Clinical Data Readout40% success